GLEN BURNIE, Md.--(BUSINESS WIRE)--The Sleep Medicine and Pulmonary Departments at Johns Hopkins University presented data in their Marfan Syndrome population at the American Thoracic Society International Conference in San Diego, CA on May 21, 2018. Support for this research was provided by the Marfan Foundation, Marfan Sleep Health Initiative (MSHI), Johns Hopkins Marfan Clinic and NovaSom, Inc.
Obstructive sleep apnea was assessed by utilizing AccuSom Home Sleep Apnea tests provided by NovaSom. The tests were provided during an annual meeting of Marfan patients and their families from all over the world in Baltimore, MD. Marfan syndrome is a genetic abnormality causing significant risk for aortic dissection. Despite being tall and thin Marfan patients have a high incidence of obstructive sleep apnea.
According to Dr Michael Coppola, Executive VP of Medical Affairs, “NovaSom is proud to have participated in this and other research projects as it reflects the confidence the researchers have in our quality and service model.” In addition to the Johns Hopkins study, NovaSom is participating in research projects with a major pharmaceutical firm as well as a medical technology company.
About NovaSom, Inc.
NovaSom, Inc. is the leader in Obstructive Sleep Apnea (OSA) home testing, with the AccuSom® Home Sleep Test, the only comprehensively supported home sleep test that provides continuous patient support and next-day test results and interpretation for health care professionals. The FDA-cleared AccuSom is as accurate as sleep lab testing, and significantly more convenient and comfortable for patients. NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider, is classified by CMS as an Independent Diagnostic Testing Facility. To learn more, please visit www.novasom.com.